Affimed N.V. Up 1.59% To $5.42 After Earnings

Affimed N.V. (AFMD) said before open Thursday that it broke even in quarter four 2023.

In the same quarter a year ago, the company lost $0.22 per share on revenue of $11.4 million.

The stock is up 1.59% to $5.42 after the report.

Affimed N.V.'s profit margins maintained as both earnings and revenue declined at the same pace.

Wall Street Analysts had an average rating of Strong Buy on the stock prior to the report.

Trading in the five days leading up to the report earned Affimed N.V. a Bullish Sentiment Rank from InvestorsObserver.

Prior to the report, InvestorsObserver gave the stock an overall score of 60. Meanwhile, the average Wall Street analyst rated the stock a Strong Buy.

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.